Triglyceride-Glucose Index and Cardiovascular Events in Kidney Transplant Recipients.

cardiovascular disease kidney transplantation metabolic syndrome triglyceride glucose index

Journal

Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 27 03 2023
revised: 20 07 2023
accepted: 16 08 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: epublish

Résumé

Kidney transplant recipients (KTRs) have an increased risk of cardiovascular (CV) events (CVEs) compared with the general population. The impact of insulin resistance on CV risk after transplantation is not well defined. We tested whether triglyceride-glucose (TyG) index, a surrogate marker of insulin resistance, may predict posttransplant CVEs in a cohort of 715 consecutive KTRs all included 1 year after transplant. Follow-up was 9.1 ± 4.6 years. Mean TyG at inclusion was 4.75 ± 0.29 (median, 4.73 [4.14-5.84]). In multiple regression analysis, having a TyG above the median value was associated with higher body mass index (BMI), low high-density lipoprotein (HDL) cholesterol level, and greater urinary protein excretion. A total of 127 CVEs (17.7%) occurred during the study period. In univariate analysis, TyG was strongly associated with CVE occurrence (hazard ratio [HR] 2.06, 95% CI 1.42-3.50, for each increase of 0.1 in TyG, Insulin resistance, as measured by the TyG index is strongly associated with CVE in KTRs. Improving insulin sensitivity seems to be a major issue to prevent CV morbidity and mortality in this high-risk population.

Identifiants

pubmed: 38025208
doi: 10.1016/j.ekir.2023.08.021
pii: S2468-0249(23)01455-9
pmc: PMC10658270
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2307-2314

Informations de copyright

© 2023 International Society of Nephrology. Published by Elsevier Inc.

Références

J Am Soc Nephrol. 2005 Apr;16(4):1091-8
pubmed: 15743998
Nephrol Dial Transplant. 2019 May 1;34(5):760-773
pubmed: 30984976
J Clin Invest. 2003 Dec;112(12):1821-30
pubmed: 14679177
Diabetes Metab Syndr. 2022 Aug;16(8):102581
pubmed: 35939943
JAMA. 2020 Nov 10;324(18):1855-1868
pubmed: 33170239
Nutr Metab Cardiovasc Dis. 2022 Mar;32(3):596-604
pubmed: 35090800
Cardiovasc Diabetol. 2022 Aug 12;21(1):155
pubmed: 35962377
J Transplant. 2011;2011:803429
pubmed: 21766010
Clin J Am Soc Nephrol. 2021 Dec;16(12):1878-1889
pubmed: 34556500
Transplantation. 2007 Jun 27;83(12):1577-81
pubmed: 17589340
Lancet Diabetes Endocrinol. 2020 Jun;8(6):477-489
pubmed: 32445735
Diabet Med. 2021 Jun;38(6):e14523
pubmed: 33434362
Diabetes Care. 2019 Sep;42(9):1645-1652
pubmed: 31296643
Lancet Healthy Longev. 2023 Jan;4(1):e23-e33
pubmed: 36521498
Kidney Int. 2021 Sep;100(3):536-545
pubmed: 33932457
Kidney Blood Press Res. 2019;44(4):669-678
pubmed: 31315123
J Transl Med. 2022 Oct 20;20(1):478
pubmed: 36266665
Cardiovasc Diabetol. 2022 Feb 10;21(1):22
pubmed: 35144621
Am J Transplant. 2015 Apr;15(4):1028-38
pubmed: 25758660
Lancet. 2018 Feb 10;391(10120):541-551
pubmed: 29221645
Transplantation. 2020 Jul;104(7):1491-1499
pubmed: 31568390
Clin Pharmacol Ther. 2017 Sep;102(3):405-419
pubmed: 28474735
J Vasc Res. 2001 Sep-Oct;38(5):415-22
pubmed: 11561143
Cochrane Database Syst Rev. 2015 Oct 25;(10):CD009580
pubmed: 26497361
Kidney Int. 2004 Jul;66(1):441-7
pubmed: 15200454
F1000Res. 2018 Jan 11;7:44
pubmed: 30210784
Rev Cardiovasc Med. 2020 Mar 30;21(1):41-56
pubmed: 32259903
BMJ Open Diabetes Res Care. 2017 Jan 13;5(1):e000283
pubmed: 28123752
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
J Intern Med. 1992 Jan;231(1):25-30
pubmed: 1732395
Eur Heart J Open. 2021 Jul 24;1(1):oeab004
pubmed: 35919094
J Pers Med. 2022 Jan 15;12(1):
pubmed: 35055431
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
Kidney Int. 2019 Dec;96(6):1374-1380
pubmed: 31611066
Clin Kidney J. 2022 Mar 10;15(9):1705-1712
pubmed: 36003671
Int J Mol Sci. 2021 Sep 24;22(19):
pubmed: 34638652
Cochrane Database Syst Rev. 2017 Jun 14;6:CD009744
pubmed: 28616955
Intern Emerg Med. 2016 Feb;11(1):61-7
pubmed: 26341217
Curr Opin Lipidol. 2022 Aug 1;33(4):237-256
pubmed: 35942811
J Clin Endocrinol Metab. 2010 Jul;95(7):3347-51
pubmed: 20484475

Auteurs

Mathilde Colladant (M)

Univ. Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Department of Nephrology, Besançon University Hospital, Besançon, France.

Melchior Chabannes (M)

Univ. Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Department of Nephrology, Besançon University Hospital, Besançon, France.

Thomas Crepin (T)

Univ. Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Department of Nephrology, Besançon University Hospital, Besançon, France.

Jamal Bamoulid (J)

Univ. Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Department of Nephrology, Besançon University Hospital, Besançon, France.

Cécile Courivaud (C)

Univ. Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Department of Nephrology, Besançon University Hospital, Besançon, France.

Didier Ducloux (D)

Univ. Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Department of Nephrology, Besançon University Hospital, Besançon, France.

Classifications MeSH